Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy

Advances in Immunology

Volumn 130, Issue , 2016, Pages 75-93

  Spranger, Stefani ^a   Sivan, Ayelet ^a   Corrales, Leticia ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer immunotherapy; Microbiota; Tumor biology

Indexed keywords

ANTIBIOTIC AGENT; BETA CATENIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CANCER IMMUNOTHERAPY; COMMENSAL; CYTOKINE PRODUCTION; DRUG MEGADOSE; GENETIC DIFFERENCE; HUMAN; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; WNT SIGNALING PATHWAY; ANIMAL; CELLULAR IMMUNITY; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTESTINE FLORA; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NEOPLASMS; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

EID: 84956896266     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/bs.ai.2015.12.003     Document Type: Chapter

References (62)

1. Abt M.C., et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012, 37:158-170. 10.1016/j.immuni.2012.04.011.
2. Bak S.P., et al. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor tolerized CD8 T cells. Journal of Immunology 2012, 189:1708-1716. 10.4049/jimmunol.1201271.
3. Baldwin A.S. Regulation of cell death and autophagy by IKK and NF-kappaB: Critical mechanisms in immune function and cancer. Immunological Reviews 2012, 246:327-345. 10.1111/j.1600-065X.2012.01095.x.
4. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942.
5. Bedognetti D., et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer 2013, 109:2412-2423. 10.1038/bjc.2013.557.
6. Bosenberg M., et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006, 44:262-267. 10.1002/dvg.20205.
7. Bronte V., Murray P.J. Understanding local macrophage phenotypes in disease: Modulating macrophage function to treat cancer. Nature Medicine 2015, 21:117-119. 10.1038/nm.3794.
8. Burdelya L., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. Journal of Immunology 2005, 174:3925-3931.
9. Cheung A.F., Dupage M.J., Dong H.K., Chen J., Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Research 2008, 68:9459-9468. 10.1158/0008-5472.CAN-08-2634.
10. Compeer E.B., Flinsenberg T.W.H., van der Grein S.G., Boes M. Antigen processing and remodeling of the endosomal pathway: Requirements for antigen cross-presentation. Frontiers in Immunology 2012, 3. 10.3389/fimmu.2012.00037.
11. Corrales L., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports 2015, 11:1018-1030. 10.1016/j.celrep.2015.04.031.
12. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: A magic bullet?. Science 2013, 339:286-291. 10.1126/science.1232227.
13. Damsky W.E., et al. beta-Catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20:741-754. 10.1016/j.ccr.2011.10.030.
14. Dankort D., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009, 41:544-552. 10.1038/ng.356.
15. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 2002, 3:991-998. 10.1038/ni1102-991.
16. Edelson B.T., et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+conventional dendritic cells. The Journal of Experimental Medicine 2010, 207:823-836. 10.1084/jem.20091627.
17. Engelhardt J.J., et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012, 21:402-417. 10.1016/j.ccr.2012.01.008.
18. Erdag G., et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Research 2012, 72:1070-1080. 10.1158/0008-5472.CAN-11-3218.
19. Fuertes M.B., Woo S.R., Burnett B., Fu Y.X., Gajewski T.F. Type I interferon response and innate immune sensing of cancer. Trends in Immunology 2013, 34:67-73. 10.1016/j.it.2012.10.004.
20. Fuertes M.B., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+dendritic cells. The Journal of Experimental Medicine 2011, 208:2005-2016. 10.1084/jem.20101159.
21. Ganal S.C., et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012, 37:171-186. 10.1016/j.immuni.2012.05.020.
22. Greten F.R., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013.
23. Hamid O., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine 2011, 9:204. 10.1186/1479-5876-9-204.
24. Harlin H., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Research 2009, 69:3077-3085. 10.1158/0008-5472.CAN-08-2281.
25. Hildner K., et al. Batf3 deficiency reveals a critical role for CD8alpha+dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100. 10.1126/science.1164206.
26. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273. 10.1126/science.1223490.
27. Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-Dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. The Journal of Experimental Medicine 2013, 210:2057-2069. 10.1084/jem.20130783.
28. Ihara S., et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Research 2012, 72:2990-2999. 10.1158/0008-5472.CAN-11-4062.
29. Iida N., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970. 10.1126/science.1240527.
30. Ivanov I.I., Honda K. Intestinal commensal microbes as immune modulators. Cell Host & Microbe 2012, 12:496-508. 10.1016/j.chom.2012.09.009.
31. Ivanov I.I., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498. 10.1016/j.cell.2009.09.033.
32. Jancic C., et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nature Cell Biology 2007, 9:367-378. 10.1038/ncb1552.
33. Kabashima K., et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. The American Journal of Pathology 2007, 171:1249-1257. 10.2353/ajpath.2007.070225.
34. Larkin J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine 2015, 373:23-34. 10.1056/NEJMoa1504030.
35. Mackey M.F., et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. Journal of Immunology 1998, 161:2094-2098.
36. Mikucki M.F.D., Matsuzaki J., Skitzki J., Gaulin N., Muhitch J., Ku A., et al. Non-redundant requirement for CXCR3 signaling during tumoricidal T cell trafficking across tumor vascular checkpoints. Nature Communications 2015, 6:7458.
37. Mittendorf E.A., et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunology Research 2014, 2:361-370. 10.1158/2326-6066.CIR-13-0127.
38. Muthuswamy R., et al. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Research 2012, 72:3735-3743. 10.1158/0008-5472.CAN-11-4136.
39. Nukiwa M., et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. European Journal of Immunology 2006, 36:1019-1027. 10.1002/eji.200535549.
40. Pan J., et al. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunology Letters 2004, 94:141-151. 10.1016/j.imlet.2004.05.003.
41. Pettit A.R., et al. Nuclear localization of RelB is associated with effective antigen-presenting cell function. Journal of Immunology 1997, 159:3681-3691.
42. Pikarsky E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466. 10.1038/nature02924.
43. Quigley D., et al. Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53. Molecular Cancer Research: MCR 2015, 13:493-501. 10.1158/1541-7786.MCR-14-0387.
44. Rutkowski M.R., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015, 27:27-40. 10.1016/j.ccell.2014.11.009.
45. Salerno E.P., Olson W.C., McSkimming C., Shea S., Slingluff C.L. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. International Journal of Cancer. Journal international du cancer 2014, 134:563-574. 10.1002/ijc.28391.
46. Schmid M.C., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727. 10.1016/j.ccr.2011.04.016.
47. Scholer A., Hugues S., Boissonnas A., Fetler L., Amigorena S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity 2008, 28:258-270. 10.1016/j.immuni.2007.12.016.
48. Sivan A., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089. 10.1126/science.aac4255.
49. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523(7559):231-235. 10.1038/nature14404.
50. Spranger S., et al. Up-regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Science Translational Medicine 2013, 5:200ra116. 10.1126/scitranslmed.3006504.
51. Spranger S., et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for Immunotherapy of Cancer 2014, 2:3. 10.1186/2051-1426-2-3.
52. Stober C.B., Brode S., White J.K., Popoff J., Blackwell J.M. Slc11a1, formerly Nramp1 is expressed in dendritic cells and influences major histocompatibility complex class II expression and antigen-presenting cell function. Infection and immunity 2007, 75:5059-5067. 10.1128/iai.00153-07.
53. Sullivan R.J., et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. Journal of Clinical Oncology 2009, 27:9003.
54. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
55. Toso A., et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Reports 2014, 9:75-89. 10.1016/j.celrep.2014.08.044.
56. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571. 10.1038/nature13954.
57. Uccellini L., et al. IRF5 gene polymorphisms in melanoma. Journal of Translational Medicine 2012, 10:170. 10.1186/1479-5876-10-170.
58. Viaud S., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976. 10.1126/science.1240537.
59. Wang T., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2004, 10:48-54. 10.1038/nm976.
60. Woo S.R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842. 10.1016/j.immuni.2014.10.017.
61. Xue W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660. 10.1038/nature05529.
62. Zhang L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 2003, 348:203-213. 10.1056/NEJMoa020177.